This one-and-a-half-day event, featuring world renowned experts, will focus on the latest research in the top three urological cancers – bladder, kidney, and prostate.
Tremendous advancements have been made in diagnosis and treatment with the recent FDA approval of a targeted therapy for metastatic bladder cancer with FGFR3 or FGFR2 genetic alterations, two combination immunotherapy-targeted therapies as first-line treatment for advanced RCC, as well as advances in diagnostics and immunotherapy research for prostate cancer
Take advantage of this highly anticipated event and immerse yourself in the evolving landscape of urological cancer care.
Click here to view the programme agenda.
|Click here to register now!|
Berlin Marriott Hotel
10785 Berlin, Germany
Berlin is serviced by Berlin Schönefeld Airport, Berlin Tegel Airport and Berlin Central Station (for transportation by train).
|Category||Early Rate by September 15||Regular Rate|
|Urologists, medical oncologists, radiation oncologists, other specialists||€100||€150|
This programme is made possible by unrestricted educational grants provided by Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd and Ferring Pharmaceuticals.